Chandramouli R

“Approving a drug is only half the journey. The true story unfolds where science, ethics, commerce, and access collide.” Introduction Chirality reshaped regulatory science and drug development -but its impact extends far beyond the laboratory and approval desk. The commercialization of single-enantiomer drugs, especially through chiral switches, has raised important ethical and economic debates about …

Episode 8: Beyond the Approval: Ethical and Economic Dimensions of Chiral Drugs Read More »

“Science, ethics, and clinical outcomes converge at a difficult question -does the purer mirror image truly heal better?” Introduction The development of single-enantiomer drugs has been heralded as a leap forward in pharmacotherapy, promising greater efficacy, reduced side effects, and more predictable pharmacokinetics. But as the pharmaceutical industry increasingly embraced chiral switches and single-enantiomer innovations, …

Episode 7: Clinical Questions: Are Single Enantiomers Always Better? Read More »

“When a drug transforms from a blend to a single hand, is it innovation -or a clever commercial sleight of hand?“ Introduction The regulatory awakening around chiral drugs enabled not just better science but also a new strategic tool for the pharmaceutical industry: the chiral switch. This phenomenon -developing a single-enantiomer version of an already …

Episode 6: The Rise of the Chiral Switch: Strategy or Science? Read More »

Tagline: “When two mirror images offer different paths, how do regulators choose which one should become medicine?” Introduction The rise of regulatory consciousness around chiral drugs in the 1990s opened a crucial new question:If mirror-image molecules behave differently, how should the pharmaceutical industry -and regulators -decide which enantiomer to develop, approve, and market? This episode …

Episode 5: Choosing the Right Twin: Regulatory Expectations for Single Enantiomers Read More »

Tagline: “When scientific precision sharpened, so did regulatory vision -technology became the bridge between molecules and medicine.” Introduction The regulatory awakening around chiral drugs in the 1990s did not occur in isolation. It was powered, almost inevitably, by remarkable scientific and technological breakthroughs. Before sophisticated tools existed, distinguishing and isolating enantiomers was labor-intensive, error-prone, and …

Episode 4: Technology as Catalyst: How Science Enabled the Regulatory Transformation Read More »

“Science may be universal, but regulation wears many faces. Let’s journey through the world of chiral drug approval across continents.” Introduction The 1990s witnessed a revolutionary shift in the regulatory treatment of chiral drugs, spurred by major agencies like the U.S. FDA and European Medicines Agency (EMA). However, the global regulatory landscape was -and still …

Episode 3: Beyond Borders: Comparing How Global Agencies Regulate Chiral Drugs Read More »